Pediatric Selective Serotonin Reuptake Inhibitor Toxicity Differential Diagnoses
- Author: Mohamed K Badawy, MD, FAAP; Chief Editor: Timothy E Corden, MD more...
Diagnostic Considerations
Serotonin syndrome produces a clinical picture that is very similar to neuroleptic malignant syndrome (NMS). Both syndromes are associated with autonomic dysfunction, alteration of mental status, rigidity, and hyperthermia. Clinical differentiation between these syndromes is very important because management may differ. For example, chlorpromazine may be of some benefit in serotonin syndrome, whereas it may cause further deterioration in NMS. Distinctions between the syndromes include the following:
- NMS develops in association with neuroleptics, whereas serotonin syndrome develops in association with serotonergic agents
- NMS has a slow onset (days to weeks) and a slow progression of 24-72 hours, whereas serotonin syndrome has a more rapid onset and progression
- NMS is associated with bradykinesia and lead pipe rigidity, whereas serotonin syndrome is associated with hyperkinesia and less rigidity
- NMS is an idiosyncratic reaction to therapeutic doses, whereas serotonin syndrome is a manifestation of toxicity, frequently generated from the combination of 2 drugs with serotonergic activity
A study concluded that although the characteristics of serotonin syndrome are well defined, some physicians may not be aware of the phenomenon. The retrospective review reported that 5 of 7 patients with serotonin syndrome were initially diagnosed with exacerbation of their psychiatric disorder, 2 patients were diagnosed with gastroenteritis, and 1 patient was diagnosed with a severe drug overdose.[8]
Differential Diagnoses
- Hyperthyroidism
- Substance Abuse: Cocaine
- Tetanus
- Toxicity, Hallucinogens - LSD
- Toxicity, Hallucinogens - PCP
- Toxicity, Monoamine Oxidase Inhibitor
- Toxicity, Tricyclic Antidepressant
Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative Safety of Antidepressant Agents for Children and Adolescents Regarding Suicidal Acts. Pediatrics. Apr 12 2010;[Medline].
Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. May 2010;196(5):354-8. [Medline]. [Full Text].
Parks V, Philipp AW, Raje S, Plotka A, Schechter LE, Connell J, et al. Concomitant blockade of 5-HT(1A) receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study. Eur Neuropsychopharmacol. Jul 4 2011;[Medline].
Gordon JB. SSRIs and St.John's Wort: possible toxicity?. Am Fam Physician. Mar 1 1998;57(5):950,953. [Medline].
Josey ES, Tackett RL. St. John's wort: a new alternative for depression?. Int J Clin Pharmacol Ther. Mar 1999;37(3):111-9. [Medline].
Watson WA, Litovitz TL, Rodgers GC, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2005;23(5):589-666. [Medline].
Sternbach H. The serotonin syndrome. Am J Psychiatry. Jun 1991;148(6):705-13. [Medline].
Attar-Herzberg D, Apel A, Gang N, Dvir D, Mayan H. The serotonin syndrome: initial misdiagnosis. Isr Med Assoc J. Jun 2009;11(6):367-70. [Medline].
[Guideline] Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). May 2007;45(4):315-32. [Medline].

